Jpmorgan Chase & CO Ice Cure Medical Ltd. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Ice Cure Medical Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,950 shares of ICCM stock, worth $8,270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,950
Previous 5,950
-0.0%
Holding current value
$8,270
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ICCM
# of Institutions
14Shares Held
154KCall Options Held
0Put Options Held
0-
Xtx Topco LTD London, X058.9KShares$81,8230.01% of portfolio
-
Geode Capital Management, LLC Boston, MA40.5KShares$56,2290.0% of portfolio
-
Two Sigma Securities, LLC New York, NY17KShares$23,6230.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny10.9KShares$15,1500.0% of portfolio
-
Concurrent Investment Advisors, LLC Tampa, FL10KShares$13,8990.0% of portfolio
About IceCure Medical Ltd.
- Ticker ICCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 36,835,600
- Market Cap $51.2M
- Description
- IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.